Why Natural Medicine Cannot Be Funded: The Patent System, the Flexner Report, and a Century of Structural Incentives Against Plant-Based Research
Pharmaceutical companies cannot fund natural compound research and earn a return on that investment. This is not a policy decision any company has made. It is a structural constraint built into patent law. A patent requires novelty. A plant compound that exists in nature is not novel. Without a patent, there is no period of market exclusivity. Without exclusivity, competitors sell the same compound for the same price. Without the price premium that exclusivity enables, the research investment cannot be recovered.
The clinical research infrastructure of American medicine was built on this logic. The Rockefeller Foundation donated more than $50 million to medical schools teaching pharmaceutical-based medicine between 1913 and the 1930s, and nothing to schools teaching herbal or homeopathic medicine. That funding decision eliminated more than half of US medical schools, trained the physicians who practiced for the following century, and produced the clinical guidelines and prescribing standards that exist today. The natural medicine compounds that remain documented and viable were not studied out of existence. They were funded out of consideration.
The Patent Constraint That No Medical School Textbook Explains
A patent grants its holder the exclusive right to produce, sell, and profit from an invention for approximately 20 years. For pharmaceutical companies, this exclusivity period is the entire business model. The R&D investment in a new drug can reach two to three billion dollars over 10 to 15 years of development. The only way to recover that investment is to sell the resulting drug at a significant premium during the patent period before generic competition eliminates the margin.
A plant compound that has existed in nature for thousands or millions of years cannot be patented in its natural form. The compound does not meet the novelty requirement. A synthetic analog of that compound, modified structurally to produce a novel molecule with similar biological activity, can be patented. This is why pharmaceutical drug discovery from natural sources consistently takes the form of isolating, structurally modifying, and patenting a novel derivative rather than conducting clinical research on the original plant.
Willow bark contains salicylate compounds that reduce pain and inflammation. Human use of willow bark for pain is documented across thousands of years in Mesopotamian, Egyptian, Greek, and Chinese medical records. Bayer isolated the active compound, modified it to produce acetylsalicylic acid, and patented the synthesis in 1897. Aspirin is not willow bark. Aspirin is a patentable derivative of willow bark, sold at a premium during its patent period by the company that had the resources to develop and market it.
The original willow bark was not further studied at scale. There was no Bayer to fund the research.
This pattern repeats across the history of pharmaceutical medicine. The plants that yielded the medicines aspirin, digoxin, morphine, quinine, Taxol, and artemisinin were not studied further once their active compounds were isolated, modified, and patented. The research infrastructure followed the patent.
(Evidence level: 5 for the patent mechanism. 35 U.S.C. Section 102 defines the novelty requirement. This is documented law with predictable consequences for research funding direction.)
Abraham Flexner Was Not a Physician
In 1908, the Carnegie Foundation for the Advancement of Teaching commissioned an evaluation of American medical education. The evaluator was Abraham Flexner. Flexner held a bachelor's degree from Johns Hopkins University and had spent his career running a preparatory school in Louisville, Kentucky. He had no medical training, no research background, and no clinical experience.
His 1910 report, "Medical Education in the United States and Canada," recommended that American medical education be reorganized around the German university model: laboratory-based, pharmaceutical-focused, and centered on the emerging sciences of bacteriology and synthetic chemistry. The report evaluated 155 medical schools across the US and Canada and judged many of them inadequate by the standards it recommended adopting.
The evaluator was not neutral. The Carnegie Foundation, which commissioned the report, had overlapping institutional interests with the direction Flexner recommended. The German university model had been shaped by the German chemical and pharmaceutical industry. American investors with interests in the emerging pharmaceutical sector stood to benefit from an American medical education system oriented toward pharmaceutical laboratory science.
Flexner's report did not close medical schools and did not fund anything on its own. It provided a framework and a justification. The financial implementation that followed was what changed American medicine.
(Evidence level: 5 for the documented facts of Flexner's background, his lack of medical credentials, and the Carnegie Foundation's commission. Historical record available in the report itself, publicly accessible, and documented in multiple historical analyses of the period.)
The Rockefeller Money and What It Bought
Between 1913 and the late 1930s, the Rockefeller Foundation directed more than $50 million to medical schools adopting the pharmaceutical laboratory model recommended by the Flexner Report. The grants went to schools with laboratory infrastructure capable of supporting teaching and research in synthetic chemistry and bacteriology. The funding came with expectations about curriculum alignment.
Schools teaching homeopathic medicine received nothing. Schools teaching eclectic medicine, the American tradition of botanical therapeutics practiced by a substantial portion of 19th-century American physicians, received nothing. Schools teaching naturopathic medicine received nothing.
The outcome was not a scientific debate resolved in favor of pharmaceutical medicine. It was a funding asymmetry so severe that the institutions on the unfunded side could not survive. Of the 155 medical schools operating in the United States in 1910, fewer than 70 remained by 1935. The majority that closed were schools with curricula including herbal, homeopathic, or eclectic medicine. The majority that survived were those aligned with the pharmaceutical laboratory model and funded by Rockefeller and Carnegie sources.
The physicians practicing medicine in the following century were trained at institutions that had never considered plant-based medicine a legitimate subject of research. The clinical guidelines they wrote, the standards they set, and the professional organizations they founded reflected the training those institutions provided. The professional organizations that set clinical standards today descended from the organizations that physicians built.
(Evidence level: 4. Funding amounts and recipient institutions are documented in Rockefeller Foundation annual reports. E. Richard Brown's "Rockefeller Medicine Men: Medicine and Capitalism in America," University of California Press, 1979, provides the most thorough scholarly documentation of the financial architecture behind this transformation. The closure rate of medical schools is documented in historical medical education records.)
What the Funding Gap Looks Like Today
The structural consequence of the Flexner-era decisions is not a historical artifact. It is an ongoing reality measurable in current budget figures.
The National Center for Complementary and Integrative Health is the NIH institute responsible for research on natural therapies, including herbal medicine, supplements, and mind-body practices. Its fiscal year 2024 budget was approximately $150 million.
Total NIH funding in fiscal year 2024 was approximately $47 billion. NCCIH represents approximately 0.3% of total federal health research funding.
The pharmaceutical industry's reported R&D expenditure is approximately $90 billion per year, according to the Pharmaceutical Research and Manufacturers of America's annual industry profile. That investment is directed entirely at patentable compounds.
The research infrastructure that would establish or refute the clinical efficacy of natural compounds at the standard required to change medical practice does not exist on a meaningful scale. The NCCIH budget funds some research. The research it funds cannot approach the scale of clinical trial evidence that established the pharmaceutical standard of care for the same conditions.
A head-to-head trial comparing St. John's Wort to a leading antidepressant, conducted with a large enough sample and long enough follow-up to produce guideline-level evidence, would cost tens of millions of dollars. No pharmaceutical company will fund it because St. John's Wort cannot be patented, and the research investment cannot be recovered. NCCIH has funded smaller trials. The Cochrane systematic review of 29 human trials found St. John's Wort superior to placebo and comparable to standard antidepressants for mild to moderate depression with fewer reported adverse effects. That Cochrane review has not changed prescribing practice in the US. Changing practice requires the kind of evidence infrastructure that, in turn, requires the kind of funding that follows the patent.
(Evidence level: 5 for the NCCIH and NIH budget figures. Publicly documented federal data, available at nccih.nih.gov and nih.gov. Level 5 for the PhRMA R&D expenditure figure, industry-disclosed. Level 4 for the St. John's Wort Cochrane review evidence.)
The Silver Example
Silver is a naturally occurring element. It cannot be patented. Its antimicrobial properties have been documented across thousands of years in Greek, Persian, Egyptian, and Chinese medical records. Hippocrates described silver's wound-healing properties. The mechanism is understood at a molecular level: silver ions disrupt bacterial cell membranes and interfere with DNA replication across a broad spectrum of pathogens, including antibiotic-resistant strains.
Silver sulfadiazine, a patentable compound combining silver with a sulfonamide molecule, was approved by the FDA in 1968 for the treatment of burns and remains the standard of care for burn wound management today. It is prescribed by physicians. It works. The silver in silver sulfadiazine is responsible for the antimicrobial activity. The sulfonamide component makes the compound novel and patentable.
The research that would establish the clinical parameters for elemental silver in additional applications, combinations with other antimicrobials, and systemic infection contexts has not been conducted on a meaningful scale. The reason is the patent constraint. Elemental silver cannot be patented. No company can fund large-scale clinical trials of elemental silver and recoup its investment.
The compound that works in burn treatment, whose mechanism is documented at the molecular level, whose antimicrobial history predates recorded Western medicine, sits in an under-researched category, not because it was found to be ineffective in other applications but because it is not patentable in its natural form.
This is one example. The Natural Medicine Series covers ten compounds in detail. The patent constraint is the structural explanation for every one of them.
(Evidence level: 4 for silver's antimicrobial mechanism and FDA-approved applications. Level 5 for the documented historical use and the patent constraint as a legal fact. Level 5 for silver sulfadiazine's FDA approval status.)
What This Framework Explains About the Natural Medicine Series
The compounds covered in articles #202 through #210 are not obscure or historically marginal. They include plants that gave Western medicine aspirin, digoxin, morphine, quinine, Taxol, and artemisinin. They include compounds with Cochrane review evidence for clinical efficacy. They include treatments that German physicians prescribe under a regulatory framework that evaluates them differently from the US system.
These compounds are not part of the American clinical standard of care because the clinical standard of care was built by institutions that the Rockefeller Foundation funded, sustained by the research infrastructure that pharmaceutical R&D dollars support, and embedded in the professional organizations established in that environment. None of those institutions has a structural interest in funding research on compounds that cannot be patented.
This is not a conspiracy. No individual scientist or physician decided to suppress natural medicine. The structural incentives of the patent system, amplified by $50 million in Flexner-era funding and $90 billion in annual pharmaceutical R&D, produced a medical education and research system that is genuinely incapable of evaluating natural compounds at the scale required by the evidence to change practice.
Understanding this framework does not mean that every natural-compound claim is valid. It means that the absence of pharmaceutical research does not constitute evidence of ineffectiveness. The evidence gap and the finding of ineffectiveness are not the same thing. ATH evaluates each compound based on the existing evidence, discloses the quality of the evidence, and identifies who funded it.
Follow the Funding
For this article, the funding trail is the subject rather than a section of it. The funding relationships are documented throughout the body above. A summary of the documented financial chain:
The Carnegie Foundation commissioned the Flexner Report. The Rockefeller Foundation funded its implementation with more than $50 million to pharmaceutical-aligned medical schools. John D. Rockefeller's Standard Oil interests extended into the petrochemical supply chain of the emerging synthetic pharmaceutical industry. The medical schools that received Rockefeller funding trained the physicians who built the clinical organizations that set prescribing standards. Those standards exclude natural compounds that cannot be patented.
The ongoing version of this trail: the pharmaceutical industry funds approximately $90 billion in annual R&D. The pharmaceutical industry's lobbying apparatus influences the Dietary Supplement Health and Education Act, the FDA's regulatory framework for supplements, and the composition of the Dietary Guidelines Advisory Committee. The institutions that have not funded natural medicine research are the same institutions with the most to gain from the existing pharmaceutical standard of care.
The researchers who have conducted natural compound research, Philippe Grandjean on fluoride, Carlos Monteiro on ultra-processed food, and the NTP on fluoride neurotoxicity, are largely funded by government agencies and academic institutions without pharmaceutical financial relationships. Their findings consistently face resistance from the institutions that the funded system built.
What Is Proven, Plausible, and Unknown
Proven (Level 4-5 evidence): Patent law requires novelty, and natural plant compounds cannot be patented in their natural form (Level 5. 35 U.S.C. Section 102, documented law). Abraham Flexner held no medical credentials, and his 1910 report was funded by the Carnegie Foundation (Level 5. Historical record, report publicly available). The Rockefeller Foundation donated more than $50 million to pharmaceutical-model medical schools between 1913 and the 1930s (Level 4. Rockefeller Foundation annual reports, scholarly documentation). More than half of US medical schools operating in 1910 had closed by 1935 (Level 4. Historical medical education records). NCCIH receives approximately 0.3% of the total NIH budget (Level 5, publicly documented federal budget). Silver sulfadiazine is FDA-approved for burn treatment, and its antimicrobial mechanism is documented (Level 5, FDA drug label, pharmacology literature). Cochrane review of 29 St. John's Wort trials found it comparable to standard antidepressants for mild to moderate depression with fewer adverse effects (Level 4. Cochrane systematic review).
Plausible: mechanism documented, full scope not quantifiable (Level 2-3): The structural funding gap has produced systematic underestimation of the clinical efficacy of natural compounds that would prove effective if studied at the scale pharmaceutical compounds are studied (Level 3. The logic is mechanistically sound; the scope of missed efficacy cannot be quantified from existing evidence).
Unknown (Level 1): The full scope of natural compound efficacy that remains undiscovered or under-studied due to the funding gap. By definition, this cannot be known from the existing evidence base, because evidence is absent rather than negative.
The Risk/Reward Verdict
ATH Verdict: Worth Investigating Further
This article establishes the structural framework for evaluating evidence from natural compounds, not a specific treatment recommendation. The framework itself is documented and provable. The implication that the absence of pharmaceutical research does not equal the absence of efficacy is a logical consequence of the documented funding structure, not a claim about any specific compound. Each compound in the Natural Medicine Series is evaluated based on the evidence specific to it, with the quality of that evidence disclosed. The reader who understands why natural medicine cannot be funded is equipped to evaluate evidence on natural compounds independently and without deferring to the pharmaceutical research infrastructure as the sole arbiter of what works.
What To Do Today
Three actions that apply the framework from this article:
First: when evaluating any health claim, natural or pharmaceutical, ask who funded the research before accepting the conclusion. The conflict of interest that makes pharmaceutical companies unreliable funders of natural compound research is the same one that makes natural compound supplement companies unreliable funders of research on their own products. The reliable funding source is the one with no financial stake in the conclusion. Look for that source.
Second: search the NCCIH research database at nccih.nih.gov/research for any natural compound you are considering. The NCCIH has funded trials on many compounds, and the results are publicly available. This is where the federally funded independent research lives.
Third: treat the absence of pharmaceutical research as a funding gap, not as a finding of ineffectiveness. For each compound in the Natural Medicine Series, ATH identifies the evidence, its quality, and who funded it. The standard of care is not the standard of evidence. It is the standard of evidence that pharmaceutical companies fund.
Go Verify
Read the Flexner Report directly. Search "Flexner Report 1910 Carnegie," and you will find it as a publicly available PDF. Read the introduction and the section on state regulation. Notice that the evaluator discusses closing schools teaching natural medicine on administrative grounds, not on evidence of ineffectiveness. The mechanism of elimination was the withdrawal of funding, not scientific refutation.
Search the Rockefeller Archive Center at rockarch.org for Rockefeller Foundation medical education grants. The foundation's own historical records document the amounts and recipient institutions.
Go to nccih.nih.gov and find the current NCCIH budget figure. Then go to nih.gov and find the total NIH budget. Calculate the percentage. Compare it to the pharmaceutical industry R&D expenditure figure from PhRMA's annual industry profile.
Search the Cochrane Library at cochranelibrary.com for the systematic review on St. John's Wort and depression. Read the conclusion on efficacy and adverse effects. Then ask: why is this compound, with this level of evidence, not in the prescribing guidelines for American physicians?
Ask a physician or pharmacist: how many hours of your medical education covered herbal or botanical medicine? For most physicians trained at US allopathic medical schools, the answer is close to zero. That is not a criticism of individual physicians. It is the documented consequence of who funded medical education for a century.
Sources and Citations
- Flexner A. "Medical Education in the United States and Canada." Carnegie Foundation for the Advancement of Teaching. Bulletin No. 4. 1910. Publicly available at Carnegie Foundation archives.
- Brown ER. "Rockefeller Medicine Men: Medicine and Capitalism in America." University of California Press. 1979.
- Eisenberg DM, Davis RB, Ettner SL, et al. "Trends in Alternative Medicine Use in the United States, 1990-1997: Results of a Follow-up National Survey." JAMA. 1998;280(18):1569-1575.
- National Center for Complementary and Integrative Health. "Budget and Appropriations." nccih.nih.gov. Fiscal Year 2024.
- Pharmaceutical Research and Manufacturers of America. "PhRMA Annual Membership Survey." 2024. phrma.org.
- Linde K, Berner MM, Kriston L. "St John's Wort for major depression." Cochrane Database of Systematic Reviews. 2008;4:CD000448.
- US Code. 35 U.S.C. Section 102. "Conditions for patentability; novelty." Legal Information Institute, Cornell Law School.